Press releases
- Lineage Receives Grant From California Institute for Regenerative Medicine (CIRM)
- Lineage Announces Changes to Board of Directors
- Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development
- Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor Symposium
- RG6501 (OpRegen®) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit
- RG6501 (OpRegen®) Preclinical Engraftment Results to Be Presented at 2024 Association for Research in Vision and Ophthalmology Meeting
- Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 7, 2024
- Lineage Announces FDA Clearance of IND Amendment for OPC1 Cell Transplant for the Treatment of Spinal Cord Injury
- Lineage Cell Therapeutics Announces Closing of $14.0 Million Registered Direct Offering
More ▼
Key statistics
As of last trade Lineage Cell Therapeutics Inc (BT3:DUS) traded at 1.02, 3.03% above its post-IPO low of 0.99, set on Apr 25, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.02 |
---|---|
High | 1.02 |
Low | 1.02 |
Bid | 1.04 |
Offer | 1.12 |
Previous close | 0.995 |
Average volume | 0.00 |
---|---|
Shares outstanding | 188.53m |
Free float | 187.72m |
P/E (TTM) | -- |
Market cap | 213.04m USD |
EPS (TTM) | -0.1243 USD |
Data delayed at least 15 minutes, as of May 02 2024 08:31 BST.
More ▼